找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia; W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V

[復(fù)制鏈接]
查看: 43492|回復(fù): 38
樓主
發(fā)表于 2025-3-21 17:27:44 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia
編輯W. Hiddemann,R. Mertelsmann
視頻videohttp://file.papertrans.cn/666/665209/665209.mp4
圖書封面Titlebook: New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia;  W. Hiddemann,R. Mertelsmann Conference proceedings 1990 Springer-V
描述Since the introduction of new anthracycline derivatives and anthrachi- none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig- nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys- plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate- dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable
出版日期Conference proceedings 1990
關(guān)鍵詞Aclacinomycin A; Akute Leuk?mie; Myelodysplast; Onkologie; Syndrom
版次1
doihttps://doi.org/10.1007/978-3-642-75720-4
isbn_softcover978-3-540-52613-1
isbn_ebook978-3-642-75720-4
copyrightSpringer-Verlag Berlin Heidelberg 1990
The information of publication is updating

書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影響因子(影響力)




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia影響因子(影響力)學(xué)科排名




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia網(wǎng)絡(luò)公開度




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引頻次




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia被引頻次學(xué)科排名




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia年度引用學(xué)科排名




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia讀者反饋




書目名稱New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 20:52:19 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:41:41 | 只看該作者
地板
發(fā)表于 2025-3-22 07:42:53 | 只看該作者
Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute or 5 days) and intermediate-dose cytosine arabinoside (Ara-C 1 g/m. twice daily for 4 days). Most patients had received previous therapy with high- or intermediate-dose Ara-C plus mitoxantrone (HAM, IAM) and TAD (6-thioguanine, standard-dose cytosine arabinoside, and daunorubicin). Four patients had
5#
發(fā)表于 2025-3-22 12:13:43 | 只看該作者
6#
發(fā)表于 2025-3-22 13:22:44 | 只看該作者
7#
發(fā)表于 2025-3-22 20:01:07 | 只看該作者
8#
發(fā)表于 2025-3-22 23:41:36 | 只看該作者
9#
發(fā)表于 2025-3-23 04:16:21 | 只看該作者
10#
發(fā)表于 2025-3-23 07:54:00 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-18 20:00
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
南丰县| 宜阳县| 宁乡县| 白银市| 东城区| 勃利县| 无棣县| 惠安县| 诏安县| 思茅市| 申扎县| 泌阳县| 历史| 恩施市| 竹溪县| 兴仁县| 当涂县| 南雄市| 龙州县| 台南市| 涟水县| 大渡口区| 阿城市| 雷州市| 华宁县| 政和县| 新乡县| 鄂托克前旗| 砚山县| 温宿县| 泰兴市| 大城县| 桦甸市| 湘潭市| 海安县| 寻甸| 平定县| 乌审旗| 禄劝| 木里| 韩城市|